Rise of sodium-glucose cotransporter 2 inhibitors in the management of nonalcoholic fatty liver disease

被引：0
|
作者：
Amr Dokmak [1 ,2 ]
Mohammad Almeqdadi [1 ,2 ]
Hirsh Trivedi [3 ]
Sandeep Krishnan [2 ,4 ]
机构：
[1] Division of Medicine,St. Elizabeth’s Medical Center
[2] Tufts University School of Medicine
[3] Division of Gastroenterology,St. Elizabeth’s Medical Center
[4] Division of Gastroenterology,Beth Israel Deaconess Medical Center
来源：
World Journal of Hepatology | 2019年 / 07期
关键词：
Non-alcoholic fatty liver disease; Non-alcoholic steatohepatitis; Sodiumglucose cotransporter 2 inhibitors; Liver cirrhosis; Diabetes;
D O I：
暂无
中图分类号：
R575.5 [肝代谢障碍];
学科分类号：
1002 ; 100201 ;
摘要：
Non-alcoholic fatty liver disease(NAFLD) is the most common form of chronic liver disease in the Western world. It is more prevalent in male gender, and with increasing age, obesity, and insulin resistance. Besides weight loss, there are limited treatment options. The use of anti-diabetic medications has been studied with mixed results. In this review, we discuss the use of anti-diabetic medications in the management of NAFLD with a specific focus on sodium-glucose cotransporter 2 inhibitors. We shed light on the evidence supporting their use in detail and discuss limitations and future directions.
引用
收藏
页码：562 / 573
页数：12
相关论文
共 50 条
  • [1] Rise of sodium-glucose cotransporter 2 inhibitors in the management of nonalcoholic fatty liver disease
    Dokmak, Amr
    Almeqdadi, Mohammad
    Trivedi, Hirsh
    Krishnan, Sandeep
    WORLD JOURNAL OF HEPATOLOGY, 2019, 11 (07) : 562 - 573
  • [2] Sodium-glucose Cotransporter 2 Inhibitors and Nonalcoholic Fatty Liver Disease
    Salah, Husam M.
    Fudim, Marat
    HEART FAILURE CLINICS, 2022, 18 (04) : 625 - 634
  • [3] THE EFFECT OF SODIUM-GLUCOSE COTRANSPORTER-2 ON NONALCOHOLIC FATTY LIVER DISEASE
    Kuhareva, Elena
    Mankieva, Eliza
    Tarasova, Olga
    Moyam, Yannick Ngameni
    GASTROENTEROLOGY, 2023, 164 (06) : S1433 - S1433
  • [4] Quantitative effects of sodium-glucose cotransporter-2 inhibitors on liver functions in patients with nonalcoholic fatty liver disease
    Chen, Xiao
    Xu, Chang
    Hu, Ke
    Yang, Yang
    Zhang, Yi-Jia
    Shi, Hao-Zhe
    Gu, Qian
    He, Su-Mei
    Zhang, Cun
    Wang, Dong-Dong
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2023, 16 (10) : 991 - 998
  • [5] Role of sodium-glucose co-transporter-2 inhibitors in the management of nonalcoholic fatty liver disease
    Anastasia Kontana
    Konstantinos Tziomalos
    World Journal of Gastroenterology, 2019, (28) : 3664 - 3668
  • [6] Role of sodium-glucose co-transporter-2 inhibitors in the management of nonalcoholic fatty liver disease
    Kontana, Anastasia
    Tziomalos, Konstantinos
    WORLD JOURNAL OF GASTROENTEROLOGY, 2019, 25 (28) : 3664 - 3668
  • [7] Sodium-glucose co-transporter 2 inhibitors in nonalcoholic fatty liver disease
    Makri, Evangelia S.
    Goulas, Antonis
    Polyzos, Stergios A.
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2021, 907
  • [8] Sodium-Glucose Cotransporter-2 Inhibitors for Treatment of Nonalcoholic Fatty Liver Disease: A Meta-Analysis of Randomized Controlled Trials
    Mantovani, Alessandro
    Petracca, Graziana
    Csermely, Alessandro
    Beatrice, Giorgia
    Targher, Giovanni
    METABOLITES, 2021, 11 (01) : 1 - 11
  • [9] Sodium-glucose Cotransporter-2 Inhibition And Exercise Affect Pathways Related To Nonalcoholic Fatty Liver Disease
    Linden, Melissa A.
    Bracken, Eric
    Zhang, Qian
    Peelor, Frederick F., III
    Miller, Benjamin F.
    Braun, Barry
    Noland, Robert C.
    Hamilton, Karyn L.
    MEDICINE & SCIENCE IN SPORTS & EXERCISE, 2024, 56 (10) : 170 - 170
  • [10] Impact of Sodium Glucose Cotransporter 2 Inhibitors on Nonalcoholic Fatty Liver Disease Complicated by Diabetes Mellitus
    Zhang, Enxiang
    Zhao, Yang
    Hu, Hongbo
    HEPATOLOGY COMMUNICATIONS, 2021, 5 (05) : 736 - 748
12345